Tremfya — Sales to customers (Note 9)
Johnson & Johnson Tremfya — Sales to customers (Note 9) increased by 1.2% to $1.61B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 68.2%, from $956.00M to $1.61B. Over 4 years (FY 2021 to FY 2025), Tremfya — Sales to customers (Note 9) shows an upward trend with a 24.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong market penetration, successful commercial execution, or expanded clinical indications, while a decrease may signal increased competition, patent expiration, or loss of market share.
Detailed definition
This metric represents the total net revenue generated from the sale of a specific pharmaceutical product line within th...
Peer comparison
Comparable to specific drug or therapeutic class revenue reported by other large-cap pharmaceutical companies.
jnj_segment_tremfya_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $479.00M | $537.00M | $693.00M | $590.00M | $597.00M | $729.00M | $752.00M | $640.00M | $706.00M | $891.00M | $910.00M | $808.00M | $906.00M | $1.01B | $949.00M | $956.00M | $1.19B | $1.42B | $1.59B | $1.61B |
| QoQ Change | — | +12.1% | +29.1% | -14.9% | +1.2% | +22.1% | +3.2% | -14.9% | +10.3% | +26.2% | +2.1% | -11.2% | +12.1% | +11.1% | -5.8% | +0.7% | +24.1% | +20.1% | +11.6% | +1.2% |
| YoY Change | — | — | — | — | +24.6% | +35.8% | +8.5% | +8.5% | +18.3% | +22.2% | +21.0% | +26.3% | +28.3% | +13.0% | +4.3% | +18.3% | +30.9% | +41.4% | +67.4% | +68.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's tremfya — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported tremfya — sales to customers (note 9) of $1.61B in Q1 2026.
- How has Johnson & Johnson's tremfya — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's tremfya — sales to customers (note 9) increased by 68.2% year-over-year, from $956.00M to $1.61B.
- What is the long-term trend for Johnson & Johnson's tremfya — sales to customers (note 9)?
- Over 4 years (2021 to 2025), Johnson & Johnson's tremfya — sales to customers (note 9) has grown at a 24.8% compound annual growth rate (CAGR), from $2.13B to $5.16B.
- What does tremfya — sales to customers (note 9) mean?
- The total net revenue earned from sales of a specific pharmaceutical product.